Ryu Kariyawasam-Chavez, Content Associate

Gwen Nichols shares her dream of changing the landscape of pediatric cancer research and care.

WHI data link radon exposure to higher ovarian cancer risk and deaths; learn how home testing may reduce cancer risk in high-radon areas.

FDA fast track designation advances oral EP300/CBP inhibitor OPN-6602 for relapsed/refractory multiple myeloma, highlighting novel hematology-oncology options and key pharmacist considerations.

Cristian Tomasetti, PhD, explains how obesity enlarges organs, raising cancer risk, and how GLP-1 weight loss therapy may reverse this, guiding oncology pharmacists.

In AML, sialylated CD43 blocks immune clearance beyond CD47, revealing new leukemia targets to boost macrophage phagocytosis.

LTOT opioid therapy declines, but gabapentinoid coprescribing rises—impact on chronic pain management, safety, and prescriptions.

Therapy-related acute myeloid leukemia (tAML) increases as cancer therapy improves, spotlighting AML risk after chemotherapy or radiation and the need for vigilant oncology monitoring.

Phase 3 trial data show that isatuximab quadruplet improves MRD negativity in transplant-eligible patients with multiple myeloma.

Meitheal Pharmaceuticals launches propofol sedation vials for ICU and surgery, cutting waste and dosing errors with 3 single-dose sizes.